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The purpose of this exploratory physiological study was to evaluate the effects of inhaled flutica-
sone/salmeterol combination (FSC) on sensory and physiological responses to exercise in subjects
withmild-to-moderate COPD. In a randomized, double-blind, placebo-controlled, crossover stud-
y, subjects underwent 6-week treatments with FSC or placebo (PLA). Detailed pulmonary function
and constant-work rate cycle exercise testswere performed following each treatment period. Fif-
teen subjects completed the study (mean SD): age 64 10 years; smoking history 47 29 pack-
years; post-bronchodilator forced expiratory volume in 1 s 86 15 %predicted (10mild and 5mod-
erateCOPD); peak incremental oxygenuptake 71 16%predicted. Comparedwith PLA, FSC treat-
ment was associated with improved: FEV1 by 0.23 0.18 L; inspiratory capacity by 0.18 0.23 L;
functional residual capacity by 0.28  0.30 L; and specific airways resistance by
4.6 4.5 cmH2O s (all p< 0.01). Therewere no significant changes in dyspnea intensity through-
out exercise and endurance time did not change significantly (1.2 3.0 min, pZ 0.149). Follow-
ing FSC, inspiratory capacity at rest and throughout exercise increased by 0.2e0.3 L with
concomitant increases in tidal volume and ventilation (p < 0.05). Compared with PLA, the work
of breathing and the ratio of respiratory muscle effort to tidal volume improved with FSC during
exercise (p< 0.05). Inmild-to-moderate COPD, FSCwas associatedwith significant improvements
in airway function at rest and during exercise. Despite important mechanical improvements,
there were no significant effects on dyspnea intensity and exercise endurance.
ª 2013 Elsevier Ltd. All rights reserved.espiratory and Critical Care Medicine Queen’s University, 102 Stuart Street Kingston, ON, Canada K7L-
13 548 1307.
.ca (D.E. O’Donnell).
3 Elsevier Ltd. All rights reserved.
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21Increased peripheral airways resistance is the hallmark of
chronic obstructive pulmonary disease (COPD) and is known
to be present even in patients with relatively preserved
spirometry. Studies have shown active airway inflamma-
tion, loss or narrowing of peripheral airways (2e2.5 mm)1,2
and increased ventilation-to-perfusion mismatching in pa-
tients with mild COPD.3,4 Such patients may also exhibit
evidence of increased airway wall thickness and structural
emphysema.5e7 Well-established manifestations of small
airway dysfunction in mild COPD include: premature airway
closure, mal-distribution of ventilation and increased air-
trapping.3,8,9 Recent cross-sectional studies confirm the
vast physiological heterogeneity in mild COPD. For exam-
ple, many individuals with mild COPD have clinically sig-
nificant increases in airways resistance and static lung
volumes as well as decreases in diffusing capacity for car-
bon monoxide, in highly variable combinations.9
Collectively, these diverse physiological abnormalities
likely explain, at least in part, why many patients with mild
COPD show increased activity-related dyspnea, reduced
daily physical activity levels and decreased health-related
quality of life, compared with non-smoking healthy indi-
viduals.10e13 Indeed, when challenged with exercise, pa-
tients with mild COPD demonstrate higher ventilatory
requirements, greater respiratory mechanical constraints,
greater dyspnea intensity and exercise intolerance com-
pared with healthy controls.12,14 The main focus of this
study was to better understand the respiratory mechanical
derangements that exist in mild-to-moderate COPD and to
determine if they can be favorably manipulated by
pharmacotherapy.
Beyond the imperative of smoking cessation, there are
no evidenced-based guidelines to support the routine use of
pharmacotherapy in milder COPD. Nevertheless, it seems
reasonable to consider pharmacotherapy in selected in-
dividuals with troublesome dyspnea and activity restric-
tion. Such patients are rarely included in clinical trials and
it remains uncertain if traditional efficacy measures (e.g.,
an arbitrary increase in FEV1) are relevant in this sub-
population or whether other measures such as lung hyper-
inflation are more sensitive. A recent physiological study
showed that acute administration of nebulised ipratropium
bromide was associated with modest but consistent im-
provements in airway function and operating lung volumes
during exercise.15 Inhaled corticosteroids (ICS) are not
recommended for mild COPD; however, there is some evi-
dence that ICS monotherapy can improve airway hyper-
responsiveness and chronic dyspnea in mild COPD.16
Studies suggest that when ICS and long-acting b2 agonists
(LABA) are delivered as fixed combination in a single
inhaler, their effect on respiratory symptoms and airway
function is superior to the LABA component alone.17e19
Worth et al.20 recently demonstrated that treatment with
combined budesonide/formoterol therapy was associated
with greater cycle endurance time (by 69 s) compared with
formoterol alone in patients with moderate-to-severe
COPD. These trends are consistent with another study
that conducted a secondary analysis on the effects of flu-
ticasone/salmeterol combination and salmeterol alone onpopulation. Fluticasone (500 mg b.i.d.) added to founda-
tional long-acting bronchodilator treatment has also been
shown to significantly improve exercise endurance com-
pared with placebo.22 Collectively, these studies suggest
that when ICS is added to LABA, bronchodilation and lung
deflation are amplified and exercise tolerance is improved.
The mechanisms for this amplification are disputed but
non-genomic local vasoconstriction effects have been sug-
gested.23 To our knowledge, there are no studies that have
examined the physiological and sensory consequences of
combination therapy in mild-to-moderate COPD. Accord-
ingly, in order to better understand the physiological ab-
normalities and the impact of pharmacotherapy in milder
COPD, we conducted a detailed physiological study to
determine the effect of inhaled fluticasone 250 mg/salme-
terol 50 mg combination (FSC) taken twice daily in a pla-
cebo-controlled crossover study. Specifically, we
evaluated the effects of 6 weeks treatment with FSC on
detailed respiratory mechanics, dyspnea intensity and ex-
ercise endurance in a group of subjects with mild-to-
moderate COPD and reduced exercise tolerance.
Methods
Subjects included clinically stable subjects 40 years with
mild-to-moderate COPD according to the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guidelines
(i.e., post-bronchodilator FEV1 to forced vital capacity ratio
(FEV1/FVC) <0.7 and FEV1 >60 %predicted)
24 and a ciga-
rette smoking history 20 pack-years. Subjects were
excluded if they had asthma or any disease other than
COPD that could contribute to exercise limitation or dys-
pnea or the presence of any contraindication to clinical
exercise testing.
Study design
This exploratory pilot study used a randomized, double-
blind, placebo-controlled, crossover design (ClinicalTrial.
gov ID#: NCT00559312) and it received ethical approval
from the Queen’s University Health Sciences and Affiliated
Teaching Hospitals Research Ethics Board (ID#: DMED-1065-
07). All subjects provided informed written consent prior to
participating. Two initial screening visits were designed to
establish study eligibility and characterize the study pop-
ulation: Visit 1a included medical history, clinical assess-
ment, dyspnea evaluation, pulmonary function tests, and
a symptom-limited incremental cycle exercise test; Visit 1b
included testing of pulmonary function responsiveness to
400 mg salbutamol. At Visit 2, subjects performed pulmo-
nary function tests and a constant-work rate (CWR) cycle
exercise test for familiarization purposes. Two 6-week
treatment periods with either fluticasone 250 mg/salme-
terol 50 mg combination taken by Diskus inhaler twice
daily or a matched placebo added to the daily drug regimen
were completed in randomized order with a two-week
washout period between. Pulmonary function tests and
a CWR cycle exercise test with detailed assessment of
respiratory mechanics were performed pre-treatment
(Visits 3 and 5) and post-treatment (Visits 4 and 6). Pre-
710 J.A. Guenette et al.treatment measurements were collected prior to the first
dose of study medication while post-treatment measure-
ments were conducted 120 min after dosing with study
medication.
Subjects were required to refrain from using ICSs and
long-acting muscarinic antagonists (LAMA) for at least two
weeks and LABAs for at least 48 h prior to and throughout the
study. Regularly taken short-acting anticholinergics were
permitted if stabilized for at least 6 weeks prior to and
throughout the study. Salbutamol was permitted as rescue
medication during the study. All visits were conducted in the
morning. Before each visit, short-acting b2 agonists and an-
ticholinergics were withheld for at least 4 and 12 h,
respectively. Subjects were also required to avoid caffeine,
heavy meals, alcohol, and strenuous exercise prior to visits.
Outcome measures
The exploratory endpoints of this study were dyspnea in-
tensity measured at a standardized time during CWR exer-
cise, cycle endurance time, measurements of small airway
function, detailed measurements of ventilation (VE),
breathing pattern, operating lung volumes, and esophageal
pressure (Pes)-derived indices of respiratory mechanics at
rest and during exercise. Changes in chronic activity-
related dyspnea were assessed post-treatment using the
Transition Dyspnea Index.25
Procedures
Spirometry, body plethysmography, single-breath diffusing
capacity for carbon monoxide, maximal mouth pressures,
and impulse oscillometry were performed using an auto-
mated testing system (Vs62j Body Plethysmograph,
Vmax229d Encore and Masterscreen IOS; SensorMedics,
Yorba Linda, CA) according to recommended guide-
lines.26e30 The single-breath nitrogen test was used to
assess the alveolar plateau (N2 slope) and closing vol-
ume.8,31 Static lung compliance (CLst) and lung recoil
pressure (PLst) were also measured (Vs62j; SensorMedics).
Pulmonary function measurements were expressed as per-
centages of predicted normal values.32e36
Symptom-limited exercise tests were conducted on an
electronically braked cycle ergometer (Ergometrics 800S;
SensorMedics) using a cardiopulmonary exercise testing
system (Vmax229d; SensorMedics). The incremental cycle
test consisted of stepwise increases in work rate of 10W/min
with peak work rate (Wpeak) defined as the greatest work
rate the subject could sustain for at least 30 s. CWR cycle
tests on subsequent visits were performed at 85%Wpeak with
endurance time defined as the duration of loaded pedaling.
Cardiopulmonary parameters, breathing pattern and Pes-
derived measurements of respiratory mechanics were
assessed on a breath-by-breath basis. Operating lung vol-
umes were derived from inspiratory capacity (IC) measure-
ments performed at rest, every second minute during
exercise and at end-exercise. Heart rate, oxyhemoglobin
saturation and blood pressure were measured using elec-
trocardiography, pulse oximetry and sphygmomanometry,
respectively. Subjects rated the intensity of their “breathing
discomfort” and “leg discomfort” at rest, every minuteduring exercise and at end-exercise using the modified 10-
point Borg scale.37 At exercise cessation, subjects were
asked about their main reason for stopping exercise and
selected various qualitative descriptors of their breathing.38
Pes was measured continuously during post-treatment ex-
ercise tests using a balloon-tipped catheter (Ackrad Labo-
ratories, Cranford, NJ) and an integrated data acquisition
system. The mechanical work of breathing (Wb) was calcu-
lated as the area within the tidal Pes-volume loop and the
additional work that fell outside of the loop representing
part of the elasticWb. An index of neuromechanical coupling
was calculated as the ratio of tidal Pes/PImax to tidal volume
(VT)/predicted vital capacity (VC)39 where PImax was the
maximal inspiratory Pes from sniff maneuvers.
40 Exercise
test data were evaluated at rest, at standardized times
during exercise and at peak exercise (the last 30-s of loaded
pedaling). Isotime was defined as the highest test duration
achieved on all testing days rounded down to the nearest full
minute where an IC maneuver was performed.
Statistical analyses
Primary statistical comparisons were performed on post-
treatment measurements of FSC versus PLA. Possible
crossover and period effects for all exploratory endpoints
were first assessed using paired t-tests according to rec-
ommended guidelines.41 Treatment responses were com-
pared using paired t-tests. Reasons for stopping exercise
and dyspnea descriptors were analyzed using McNemar’s
exact test. A p < 0.05 significance level was used for all
analyses, with Bonferroni adjustments for multiple com-
parisons where appropriate. Values are presented as
mean  SD unless otherwise specified.
Results
Eighteen subjects were enrolled prior to termination of the
study due to expiry of study medication: 3 subjects were
subsequently withdrawn (2 for personal reasons, 1 due to an
acute COPD exacerbation after the first week of study
treatment), 15 subjects completed the study, and 11 of the
completed subjects had Pes-derived measurements at both
post-treatment visits. All subjects had a significant smoking
history and a diagnosis of COPD, the majority of whom (13/
18) had a diagnosis within the previous 5 years. Post-
bronchodilator FEV1/FVC ratios were <0.70 and all but two
subjects were <lower limit of normal.42 FEV1 %predicted fit
either GOLD stage I (n Z 12) or stage II (n Z 6) criteria for
COPD. Subjects had mild-to-moderate activity-related dys-
pnea, reduced symptom-limited cycle exercise capacity, as
well as an abnormal ventilatory response during exercise
(Table 1). Themajority of the sample used regular respiratory
medications: a short-acting b2 agonist as needed (n Z 10),
ipratropium (nZ 3), tiotropium (nZ 4), salmeterol (nZ 2),
fluticasone (nZ 2) and salmeterol/fluticasone (nZ 3).
Treatment responses are reported for the 15 completed
subjects (GOLD stage IZ 10; GOLD stage IIZ 5). There was
no significant crossover or period effects for any of the
exploratory endpoints. The only treatment-related adverse
event was moderate-to-severe hoarseness in 4 subjects
during the FSC arm. The Transition Dyspnea Index revealed
Table 1 Subject characteristics at baseline.
Enrolled subjects
(n Z 18)
Completed subjects
(n Z 15)
Subjects with mechanical
measurements (n Z 11)
Sex 39% male 40% male 45% male
Age, years 64  10 64  10 63  10
Body mass index, kg/m2 28.3  6.5 29.5  6.4 31.6  5.8
COPD duration, years 4.9  5.7 4.5  5.1 3.1  2.2
Cigarette smoking, pack-years 43  28 47  29 47  34
Baseline Dyspnea Index, focal score 8.3  1.5 8.3  1.6 8.5  1.7
Peak incremental VO2, L/min
(%predicted max)
1.34  0.44
(69  15)
1.39  0.46
(71  16)
1.45  0.50
(67  13)
Peak incremental work rate,
W (%predicted max)
79  29
(59  14)
79  32
(59  15)
86  33
(58  14)
Peak incremental DIC, L 0.38  0.29 0.39  0.30 0.43  0.31
Pulmonary function:
post-bronchodilator:
FEV1, %predicted 87  14 86  15 87  15
FEV1/FVC, % 60  6 61  6 60  5
pre-bronchodilator:
FEV1, %predicted 80  17 79  19 79  17
FEV1/FVC, % 58  9 58  9 57  8
SVC, %predicted 104  19 101  17 104  17
IC, %predicted 100  23 99  24 105  16
FRC, %predicted 105  16 102  16 100  13
RV, %predicted 107  23 106  24 107  24
TLC, %predicted 103  12 101  11 102  11
DLCO, %predicted 68  20 68  20 64  19
MIP, %predicted 103  28 100  27 103  27
MEP, %predicted 71  18 69  19 72  16
N2 slope, %predicted 628  676 644  724 652  811
Values are means  SD.
Abbreviations: VO2, oxygen uptake; DIC, change in inspiratory capacity from rest (i.e., magnitude of dynamic hyperinflation); FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity; SVC, slow vital capacity; IC, inspiratory capacity; FRC, functional residual
capacity; RV, residual volume; TLC, total lung capacity; DLCO, lung diffusing capacity for carbon monoxide; MIP, maximal inspiratory
mouth occlusion pressure at functional residual capacity; MEP, maximal expiratory mouth occlusion pressure at total lung capacity.
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Figure 1 Responders and non-responders for the change in
dyspnea at isotime and the Transition Dyspnea Index during
constant-work rate exercise. FSC, fluticasone/salmeterol
combination; PLA, placebo.
Effect of fluticasone/salmeterol in mild-to-moderate COPD 711modest but non-significant improvements in activity-
related dyspnea after treatment with FSC compared with
PLA (1.00  2.00 vs. 0.13  0.35 units, respectively;
p Z 0.05) (Fig. 1A).
Pulmonary function
Post-treatment pulmonary function data are shown in Table 2.
Six weeks of FSC therapy was associated with significant im-
provements in pre- (trough) and post-dose (peak) FEV1,
functional residual capacity, inspiratory capacity and specific
airways resistance. Impulse oscillometry measurements that
changed significantly included post-dose values of total
resistance at 5 Hz (R5), reactance at 5 Hz (X5) and resonant
frequency (Fres); while measurements at the higher fre-
quencies (i.e., 15 and 20 Hz) did not change. There were no
significant treatmentdifferences inclosing volumeorN2 slope.
Exercise responses
On average, dyspnea intensity during exercise was not
significantly different following FSC compared with PLA at
Table 2 Post-treatment pulmonary function (n Z 15).
PLA FSC
Trough Peak Trough Peak
FEV1, L 1.78  0.77 1.81  0.74 1.94  0.77 * 2.04  0.80 *
FEV1/FVC, % 57  7 57  8 60  6 * 60  6 *
PEF, L/s 5.19  1.80 5.23  1.73 5.62  1.78 5.72  1.80 *
FEF25e75%, L/s 0.77  0.50 0.79  0.50 0.87  0.62 0.91  0.58 *
SVC, L 3.30  1.18 3.36  1.17 3.38  1.04 3.50  1.16 *
IC, L 2.53  1.02 2.59  1.10 2.68  1.13 * 2.77  1.12 *
FRC, L 3.04  0.65 2.99  0.67 2.89  0.61 * 2.71  0.54 *
RV, L 2.26  0.71 2.21  0.69 2.20  0.68 2.04  0.62
TLC, L 5.56  1.41 5.57  1.47 5.58  1.49 5.50  1.35
sRaw, cmH2O s 13.9  6.1 14.3  7.6 11.1  5.0 * 9.6  3.6 *
DLCO, mL/min/mmHg 13.6  5.5 13.4  5.5 14.4  6.0 14.2  5.8
MIP, cmH2O 72  23 76  22 75  21 81  21
R5, cmH2O/L/s 6.9  2.2 6.9  2.1 6.6  2.2 6.1  1.8 *
X5, cmH2O/L/s 2.8  1.7 3.2  2.0 2.2  1.0 2.0  1.0 *
Fres, Hz 21.4  5.6 21.9  5.7 19.0  5.3 16.8  5.3 *
Closing volume, L e 0.46  0.32 e 0.54  0.44
N2 slope, %/L e 6.4  4.3 e 5.8  3.3
CLst, L/cmH2O # e 0.31  0.10 e 0.35  0.15
PLst, cmH2O # e 25.5  11.9 e 22.6  8.0
Values are means  SD. * p < 0.05 FSC versus PLA; # n Z 11.
Abbreviations: FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow; FEF25e75%, forced expiratory
flow between 25 and 75% of forced vital capacity; SVC, slow vital capacity; IC, inspiratory capacity; FRC, functional residual capacity;
RV, residual volume; TLC, total lung capacity; sRaw, specific airways resistance; DLCO, lung diffusing capacity for carbon monoxide; MIP,
maximal inspiratory mouth occlusion pressure at functional residual capacity; R5, resistance at 5 Hz; X5, reactance at 5 Hz; Fres,
resonant frequency; CLst, static lung compliance; PLst, static lung elastic recoil pressure.
712 J.A. Guenette et al.any given time or VE (Fig. 2). However, 6/15 subjects
experienced a 1 Borg unit decrease and 7/15 a 0.5 Borg
unit decrease in dyspnea intensity at isotime following
treatment (Fig. 1B). Primary reasons for stopping exercise
following PLA [breathing (nZ 4), legs (nZ 5), combination
of legs and breathing (n Z 5), other (n Z 1)] were not
significantly different from FSC [breathing (n Z 1), legs
(n Z 8), combination (n Z 5), other (n Z 1)].
Exercise responses are reported in Table 3. Although
there was a 1.2  3.0 min mean difference in favor of FSC in
post-treatment CWR cycle endurance time, this did not
reach statistical significance (pZ 0.149). FSC had no effectTime (min)
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exercise. Ventilatory responses to exercise are shown in
Fig. 3. VE increased during exercise with FSC as a result of
an increase in VT. IC at isotime was increased by 0.23 L,
reflecting the increase in IC at rest by 0.22 L; this resulted
in a downward shift in operating lung volumes at rest and
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exercise (w4 min) after FSC compared with PLA, the total
mechanical Wb was significantly reduced by 16 J/min (15%)
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Table 3 Sensory and physiological responses at rest, isotime and peak exercise (n Z 15).
Rest Isotime Peak
PLA FSC PLA FSC PLA FSC
Exercise time, min e e 3.3  1.4 3.3  1.4 4.5  1.6 5.7  3.7
Dyspnea, Borg 0.0  0.0 0.0  0.0 3.2  2.4 2.8  1.9 5.6  2.6 5.8  2.6
Leg discomfort, Borg 0.0  0.0 0.0  0.0 4.1  2.4 3.8  2.2 6.4  2.8 6.4  2.5
VO2, L/min 0.30  0.10 0.29  0.09 1.27  0.47 1.28  0.51 1.41  0.48 1.45  0.56
Heart rate, beats/min 79  13 83  13 116  19 118  18 126  21 128  17
SaO2, % 96  4 96  3 94  6 96  4 96  6 96  4
VE, L/min 10.2  2.6 10.7  2.7 40.4  18.1 43.8  20.5 * 51.5  20.0 55.5  22.2 *
VT, L 0.69  0.20 0.69  0.15 1.44  0.48 1.55  0.61 * 1.48  0.49 1.63  0.64 *
Fb, breaths/min 15.6  4.7 16.3  5.3 27.9  6.4 28.8  7.8 35.3  8.0 35.2  8.7
TI/Ttot 0.40  0.05 0.43  0.07 * 0.43  0.05 0.44  0.04 0.44  0.05 0.45  0.05
VE/VCO2 42  8 44  9 31  4 33  4 * 33  5 34  4 *
PETCO2, mmHg 34  3 34  4 37  5 36  4 * 35  6 34  5 *
IC, L 2.52  0.96 2.74  1.12 * 2.30  1.00 2.53  1.11 * 2.24  1.03 2.41  1.03 *
DIC, L 0.0  0.0 0.0  0.0 0.22  0.25 0.21  0.26 0.28  0.29 0.33  0.28
IRV, L 1.83  0.85 2.06  1.06 * 0.86  0.67 0.98  0.71 0.76  0.63 0.78  0.47
Pes tidal swing, cmH2O # 10  3 9  3 28  11 23  7 * 35  18 31  16 *
Wb, J/min # 6  3 5  3 82  47 76  45 138  80 135  79
Pes/PImax:VT/VCpred # 0.69  0.30 0.52  0.12 0.87  0.44 0.61  0.22 * 1.07  0.62 0.78  0.43 *
Values are means  SD. * p < 0.05 FSC versus PLA; # n Z 11.
Abbreviations: VO2, oxygen uptake; SaO2, arterial oxygen saturation; VE, minute ventilation; VT, tidal volume; Fb, breathing frequency;
TI/Ttot, inspiratory duty cycle; VE/VCO2, ventilatory equivalent for carbon dioxide; PETCO2, partial pressure of end-tidal carbon dioxide;
IC, inspiratory capacity; DIC, change in inspiratory capacity from rest; IRV, inspiratory reserve volume; Pes, esophageal pressure; Wb,
work of breathing; PImax, maximal inspiratory pressure from a sniff maneuver; VCpred, predicted vital capacity; Pes/PImax:VT/VCpred,
index of neuromechanical coupling.
Effect of fluticasone/salmeterol in mild-to-moderate COPD 713respiratory system, improved at isotime and peak exercise
following treatment with FSC by 35% and 31%, respectively
(Table 3).
Discussion
The main findings of this exploratory physiological study are
as follows: (1) compared with PLA, FSC did not significantly
improve dyspnea intensity ratings during high intensity CWR
exercise or the Transition Dyspnea Index; (2) FSC was
associated with significant improvements in trough and
peak FEV1 and airways resistance with concomitant im-
provements in FRC; (3) FSC significantly increased IC during
rest and exercise and reduced respiratory muscle effort
requirements and the mechanical Wb.
Our subjects with mild-to-moderate COPD had clear
evidence of physiological impairment and experienced
mild-to-moderate dyspnea during daily activity as meas-
ured by the Baseline Dyspnea Index. Our results therefore
add to the growing body of evidence that some patients
with mild spirometric abnormalities experience persistent
troublesome dyspnea and activity restriction.12,13 Approx-
imately 70% of the study participants were already receiv-
ing regular inhaled pharmacotherapy for their symptoms.
Despite having a relatively preserved FEV1, our subjects
showed evidence of extensive peripheral airway dysfunc-
tion which included: markedly reduced maximal mid-
expiratory flows, increased resistance at low oscillation
frequencies and mal-distribution of ventilation as measured
by single-breath N2 washout. These subjects also hadsignificantly reduced exercise tolerance: peak cycle work
rate was only 59% predicted and peak symptom-limited VO2
was only 17  4 ml/kg/min (71% predicted). In agreement
with previous studies in mild COPD, end-expiratory lung
volume increased from rest to peak incremental exercise
(by w0.4 L) and subjects experienced strong dyspnea in-
tensity at relatively low absolute work rates and ventila-
tions compared to previously studied age-matched healthy
controls.12,14 Respiratory mechanical measurements and
ventilatory responses were similar in this group to those
reported in previous studies in mild COPD.12,14,15 However,
despite these respiratory mechanical abnormalities, only 2/
15 subjects identified dyspnea as the sole reason for stop-
ping pre-treatment CWR exercise.Resting pulmonary function treatment responses
Six-week treatment with FSC was associated with signifi-
cant improvements in airway function measured by spi-
rometry, forced oscillometry and plethysmography (specific
airways resistance decreased by an average of 39%). Trough
FEV1 increased by an average of 160 ml (9%) indicating
effective sustained 12 h bronchodilation. Resting IC and VC
increased significantly, and FRC decreased confirming
a modest reduction in air-trapping. The magnitude of effect
is comparable to that observed following acute admin-
istration of high-dose nebulized ipratropium bromide in
similar subjects with mild COPD.15 However, greater
reduction in lung hyperinflation was previously seen when
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Figure 3 Ventilatory and respiratory mechanical responses to constant-work rate exercise. VE, ventilation; VT, tidal volume; Fb,
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obstruction.21
Exercise treatment responses
In keeping with previous bronchodilator studies in more
advanced COPD, VE increased at isotime and at peak ex-
ercise with FSC by 3.4 and 4.0 L/min, respectively, which
was primarily attributable to corresponding small increases
in VT expansion by 0.11 and 0.15 L. Breathing frequency
responses to exercise were similar with PLA and FSC. The
ventilatory equivalent for CO2 increased modestly following
FSC compared with PLA because of relatively greater in-
creases in the numerator (VE); accordingly, there was
a concomitant decrease in end-tidal CO2 throughout exer-
cise. Both end-inspiratory and end-expiratory lung volumes
were reduced primarily as a result of increased resting IC as
the rate of change in IC (i.e., dynamic lung hyperinflation)
was unchanged (Table 3). Lung volume reduction likely
reflected improved mechanical time constants for lungemptying mainly as a result of decreased airways resistance
since PLst was not altered post-FSC. Subjects could achieve
a higher VE throughout exercise at lower operating lung
volumes (Fig. 3) which is likely advantageous for respiratory
muscle function. Indeed, tidal Pes swings and the total
mechanical Wb were both reduced during exercise as
a result of reduced resistive and elastic loading. Moreover,
FSC treatment was associated with an improved ratio of
respiratory effort to VT (by >30% at isotime and peak ex-
ercise) suggesting a more favorable relation between cen-
tral neural drive and the mechanical response of the
respiratory system during exercise.
Dyspnea
The question arises as to why the aforementioned im-
provements in airway function and respiratory mechanics
did not translate into improved dyspnea and exercise tol-
erance for the group as a whole? This inconsistency is in
sharp contrast with the results of previous studies on the
Effect of fluticasone/salmeterol in mild-to-moderate COPD 715effects of FSC and bronchodilator therapy in subjects with
moderate-to-severe COPD.21,43 A minority of subjects (6/
15) did show improvement in dyspnea after FSC treatment
as measured by isotime dyspnea ratings of 1 Borg units or
Transition Dyspnea Index of 1 (the minimal clinically
important difference). The variable dyspnea responses
following treatment (Fig. 1) may have been attributable to
the fact that the resting IC was largely preserved in these
subjects and that in contrast to more severe COPD,44 leg
discomfort (or a combination of leg and breathing dis-
comfort) was reported as an important reason for stopping
CWR exercise in the majority. It is also possible that, unlike
the situation in previous studies of FSC efficacy in
moderate-to-severe COPD, the smaller improvements in
respiratory mechanics in milder COPD were insufficient to
counter the negative sensory effects of the attendant
increase in VE. In this regard, it is noteworthy that, in
contrast to similar bronchodilator studies in more advanced
COPD,45 FSC did not alter the relationship between dyspnea
intensity and VE during exercise in milder COPD. It remains
to be determined if alternative exercise modalities (e.g.,
treadmill), which may theoretically be associated with less
perceived leg discomfort, might prove more suitable for the
purpose of dyspnea evaluation in milder COPD.
Limitations
This was an invasive and mechanistic physiological study
that utilized a rigorous experimental approach in a rela-
tively small number of patients and not a traditional clinical
trial. As such, we may have been underpowered to detect
significant treatment differences in variables such as iso-
time dyspnea and exercise performance. As such, caution
must be made when extrapolating these data to the larger
population of patients with mild-to-moderate COPD. Nev-
ertheless, our sample size was sufficiently large to detect
consistent changes in several physiological variables in
response to FSC treatment and provided new insights into
the drugs mode of action in milder disease. This study
provides a strong rationale for future studies to identify
symptomatic patients with mild COPD who are likely to
respond to FSC treatment.
Our COPD patients had an average BMI of 29.5 kg/m2,
with 7 subjects in the obese range. This may have impli-
cations for measured lung volume components in this study
group46 and potentially for physiological and sensory re-
sponses to FSC treatment. However, this latter contention
is untested and remains speculative.
Conclusions
Compared to PLA, no consistent improvement in dyspnea
and exercise tolerance was observed in those randomized
to FSC. Our results confirm that extensive physiological
derangements and exercise intolerance can exist in some
patients with mild COPD and that FSC treatment was
associated with important improvements in respiratory
mechanics during rest and exercise. This study also shows
that traditional trough FEV1 and oscillometry measure-
ments appear to be adequately responsive to pharmaco-
logical interventions in mild COPD.Sources of support
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